Kenya receives 21,000 doses of injectable HIV prevention drug

Kenya has received 21,000 starter doses of Lenacapavir, a long-acting injectable HIV prevention drug, giving the country a shot in the arm in its fight against new infections...

✨ Key Highlights

Kenya has received 21,000 starter doses of Lenacapavir, a long-acting injectable HIV prevention drug, positioning it as the first country in East Africa to introduce this innovation. This significant delivery marks a crucial step in the nation's fight against new HIV infections, particularly among its youth.

The initial supply of 21,000 doses was financed through the Global Fund and will cost Ksh7,800 per patient annually.
Health Cabinet Secretary Aden Duale announced the drug's rollout in 15 priority counties, with an additional 12,000 continuation doses expected by April.
Kenya was among the first nine countries globally selected to introduce Lenacapavir, a twice-yearly injectable PrEP that protects HIV-negative individuals for six months.